Skip to main content

Table 2 Coexistent genetic alterations including EGFR, ROS1, and EML4-ALK in MPA and LA cases

From: A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients

Variables MPA(n = 55) LA(n = 76) p
Single alteration    0.028*
 EGFR + 40(72.7%) 41(53.9%)  
 ROS1 + 2(3.6%) 0  
 EML4-ALK+ 1(1.8%) 1(1.3%)  
Double alteration    0.043*
 EGFR+; ROS1+ 2(3.6%) 1(1.3%)  
 ROS1+; EML4-ALK+ 2(3.6%) 0  
No alteration    0.001**
 EGFR-; ROS1-; EML4-ALK- 8(14.5%) 33(43.5%)  
  1. MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component, EGFR+ EGFR mutation, EGFR- EGFR wild type, ROS1+ ROS1 fusion, ROS1- no ROS1 fusion, EML4-ALK+ EML4-ALK fusion, EML4-ALK- no EML4-ALK fusion
  2. *p<0.05; **p<0.01 compared with LA